{Reference Type}: Meta-Analysis
{Title}: Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis.
{Author}: Heidary M;Dashtbin S;Asadi A;Asadollahi P;Khatib A;Ebrahimi MA;Ghanbari Z;Darbandi A;Ghanavati R;Pakzad R;
{Journal}: Future Microbiol
{Volume}: 19
{Issue}: 0
{Year}: 2024 03 18
{Factor}: 3.553
{DOI}: 10.2217/fmb-2023-0170
{Abstract}: Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.